Abstract
Abbreviations and Acronyms:
CKD (chronic kidney disease), CV (cardiovascular), EF (ejection fraction), FDA (Food and Drug Administration), HF (heart failure), K+ (potassium), MRA (mineralocorticoid receptor antagonist), NYHA (New York Heart Association), RAAS (renin-angiotensin-aldosterone system), RCT (randomized controlled trial), SPS (sodium polystyrene sulfonate), SZC (sodium zirconium cyclosilicate)- •
Hyperkalemia (serum potassium [K+] >5.0 or >5.5 mEq/L) is a potentially life-threatening complication of chronic kidney disease (CKD). Risk factors for hyperkalemia in patients with CKD include use of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS); advanced renal impairment; comorbidities such as diabetes, hypertension, and heart failure; and consumption of a K+-enriched diet.
- •
Management of hyperkalemia in patients with CKD can be challenging because specific CKD treatments may exacerbate the potential for hyperkalemia. The recent approval of 2 new K+-binding drugs (sodium zirconium cyclosilicate [formerly ZS-9] and patiromer) provides new options for managing hyperkalemia. These drugs have the potential to ease K+ dietary restrictions in CKD and attenuate the increase in K+ during the interdialytic period.
- •
Potassium-binding drugs reduce serum K+ levels via ion exchange mechanisms in the gastrointestinal tract. Sodium zirconium cyclosilicate is a nonpolymer compound that exchanges K+ for sodium and hydrogen ions. In contrast, patiromer is a polymer that exchanges K+ for calcium ions.
- •
Sodium zirconium cyclosilicate significantly lowers serum K+ concentrations 1 hour after administration in patients with hyperkalemia and has been found to maintain serum K+ in patients with CKD and those receiving RAAS inhibitors for up to 1 year. Sodium zirconium cyclosilicate is associated with dose-related mild to moderate edema that can be managed with dose reductions or with diuretic therapy.
- •
Patiromer significantly reduces serum K+ concentrations and facilitates use of RAAS inhibitors in patients with CKD and/or heart failure who either have or are at risk of hyperkalemia. Gastrointestinal adverse effects (constipation, diarrhea, nausea, abdominal discomfort, and flatulence) are the most common adverse effects associated with patiromer.
- Yancy C.W.
- Jessup M.
- Bozkurt B.
- et al.
Disease | Recommendation | Source |
---|---|---|
CKD | ARB or ACEi to prevent CKD progression in adults with or without diabetes mellitus who have CKD and UAE >300 mg/d | KDIGO 2012 Clinical Practice Guidelines
10
|
ARB or ACEi to prevent CKD progression in adults with diabetes mellitus who have CKD and UAE 30-300 mg/d | ||
ACEi or ARB to improve kidney outcomes in patients with hypertension and CKD | JNC 8 Guidelines
20
|
|
HF | ACEi or ARB to prevent symptomatic HF in patients with reduced EF and a history of MI, and ACEi in patients with reduced EF and no MI | ACCF/AHA 2013 Guidelines
21
2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
Circulation. 2017; 136: e137-e161
|
ACEi to reduce morbidity and mortality in patients with HFrEF (LVEF ≤40%), or an ARB in ACEi-intolerant patients | ||
MRA to reduce morbidity and mortality in patients with NYHA class II-IV HF and LVEF ≤35%, and after acute MI in patients with LVEF ≤40% in whom symptoms of HF develop or who have a history of diabetes mellitus | ||
Diabetes | ACEi or ARB for first-line treatment of hypertension in patients with diabetes mellitus and urinary ACR ≥300 mg/g creatinine or 30-299 mg/g creatinine | ADA 2019 Guidelines
22
|
- Yancy C.W.
- Jessup M.
- Bozkurt B.
- et al.
Variable | Sodium zirconium cyclosilicate
35
,
36
|
Patiromer
37
,
38
|
Sodium polystyrene sulfonate
39
|
---|---|---|---|
Date of FDA approval | May 2018 | October 2015 | June 1958 |
Date of EMA approval | March 2018 | July 2017 | NA |
Chemical properties | Nonpolymer; nonabsorbed zirconium silicate | Cross-linked polymer; patiromer sorbitex calcium | Resin/polymer; sodium salt of polystyrene sulfonic acid |
Sodium content | 80 mg/g | None | ∼100 mg/g |
Mechanism of action | Preferentially captures K+ in exchange for hydrogen and sodium | Exchanges calcium for K+; also binds magnesium | Sodium-K+ exchange resin/polymer; nonspecifically binds K+, magnesium, and calcium |
Onset of action | 1 Hour | 7 Hours | Hours to days |
Dose | Initial: 10 g TID for up to 48 hours Maintenance: 10 g QD (adjust dose at weekly intervals in 5-g increments to obtain the desired serum K+ range) Usual maintenance dose: 5 g QoD to 15 g QD |
Initial: 8.4 g QD; increase dose as necessary at ≥1-wk intervals in increments of 8.4 g | 15 g (4 level teaspoons) 1-4 times daily |
Preparation | Combine powder with ≥45 mL (≥3 tablespoons) of water, stir well, and drink immediately | Combine powder with 90 mL of water, stir thoroughly to form a cloudy mixture (powder will not dissolve), and drink immediately | Combine with a small quantity of water, or for greater palatability, syrup; may also give by endogastric tube or as an enema |
Administration | Can be taken with or without food | Do not heat or add to heated foods or liquids | Oral suspension or enema |
Appearance and texture | Free-flowing, odorless, insoluble white powder for oral suspension | Off-white to light brown powder composed of spherical beads | Cream to light brown finely ground powder |
Storage | 15°-30°C (59°-86°F) | Refrigerate at 2°-8°C (35°-46°F); if stored at room temperature, use within 3 mo (avoid exposure to temperatures >40°C) | 25°C (77°F; excursions to 15°-30°C permitted) |
Site of K+ binding | GI tract | GI tract | GI tract or colon when administered by enema |
Adverse effects | Edema (mild to moderate); hypokalemia | Hypomagnesemia; hypokalemia; constipation, diarrhea, nausea, abdominal discomfort, flatulence | Intestinal necrosis; electrolyte disturbances (including hypokalemia); nausea, vomiting, constipation, diarrhea; fluid overload in patients sensitive to high sodium intake; risk of aspiration |
Drug interactions | Oral medications that exhibit pH-dependent solubility should be administered ≥2 h before or 2 h after | Take other orally administered drugs ≥3 h before or 3 h after | Take other orally administered drugs ≥3 h before or 3 h after; cation-donating antacids may reduce potassium exchange and increase risk of systemic alkalosis; concomitant use of sorbitol may contribute to risk of intestinal necrosis and is not recommended |
Methods
Hyperkalemia and Challenges for CKD Management
Effect on Diet
USDA Food Composition Databases.
General dietary K+ recommendations in adults with CKD
44
|
||||
---|---|---|---|---|
Nutrient | eGFR ≥60 mL/min/1.73 m2 with increased CKD risk | eGFR 30 to <60 mL/min/1.73 m2 | eGFR <30 mL/min/1.73 m2 | Dialysis |
K+ (g/d) | 4.7 | 4.7 | <3 | <3 |
Approximate K+ content of selected heart-healthy foods
46
,
47
US Department of Agriculture
USDA Food Composition Databases.
https://ndb.nal.usda.gov/ndb/
Date accessed: March 10, 2019
|
||||
Food group | Approximate K+ content (serving) | |||
Grains | ||||
Brown rice, cooked | 0.174 g (1 cup) | |||
Whole-wheat pasta, cooked | 0.102 g (1 cup) | |||
Whole-wheat bread | 0.081 g (1 slice) | |||
Vegetables | ||||
Tomatoes; red, ripe, cooked | 0.523 g (1 cup) | |||
Cooked spinach | 0.838 g (1 cup) | |||
Avocado; raw, California | 1.17 g (1 cup, pureed) | |||
Cooked beet greens | 1.31 g (1 cup) | |||
Fruits and fruit juices | ||||
Bananas | 0.422 g (1, medium size) | |||
Cantaloupe | 0.368 g (one-quarter, medium size) | |||
Orange juice | 0.473 g (1 cup) | |||
Low-fat or fat-free dairy | ||||
Yogurt; plain, nonfat | 0.579 g (8 oz) | |||
1%-2% Milk | 0.366 g (1 cup) | |||
Lean meats, poultry, fish | ||||
Pork loin; roasted | 0.371 g (3 oz) | |||
Chicken; dark or light meat, roasted | 0.190-0.200 g (3 oz) | |||
Cod; Pacific, cooked | 0.439 g (3 oz) |
- Pitt B.
- Anker S.D.
- Bushinsky D.A.
- Kitzman D.W.
- Zannad F.
- Huang I.Z.
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
Effect on RAAS Inhibitor Therapy Optimization
- Yancy C.W.
- Jessup M.
- Bozkurt B.
- et al.
Effect on Hemodialysis
Clinical Efficacy and Safety of K+ Binders for the Treatment of Hyperkalemia in CKD
- Pitt B.
- Anker S.D.
- Bushinsky D.A.
- Kitzman D.W.
- Zannad F.
- Huang I.Z.
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
- Pitt B.
- Anker S.D.
- Bushinsky D.A.
- Kitzman D.W.
- Zannad F.
- Huang I.Z.
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
Study design | Patient population | Study treatment | Primary efficacy end point results
c
Safety was also assessed. In clinical studies, edema (generally mild to moderate in severity) was the most commonly reported adverse reaction with SZC. SZC should not be used in patients with severe constipation, bowel obstruction, or impaction, including bowel motility disorders that occur postoperatively; it may be ineffective or worsen gastrointestinal conditions.35
|
---|---|---|---|
Phase 2, 4-d, randomized, double-blind, placebo-controlled, dose-escalating
55
|
eGFR 30-60 mL/min/1.73 m2 and serum K+ 5.0-6.0 mEq/L (n=90); RAASi: n=56 | SZC 0.3, 3, or 10 g TID or placebo for 48 h (minimum of 6 doses over 2 d or maximum of 12 doses over 4 d) | Rate of serum K+ decline in first 48 h (SZC 10 g): −0.11±0.46 mEq/L decrease in serum K+ at 1 h vs +0.12±0.36 mEq/L with placebo (P=.04) –0.92±0.52 mEq/L at 38 h vs –0.26±0.4 mEq/L with placebo (P<.001) |
Phase 3, 2-wk, randomized, double-blind, placebo-controlled, dose-ranging
78
|
Correction phase: serum K+ 5.0-6.5 mEq/L (n=754); CKD: n=463; RAASi: n=502 | Correction phase: SZC 1.25, 2.5, 5, or 10 g TID or placebo for 48 h | Correction phase: between-group difference in exponential rate of serum K+ change/h in first 48 h: –0.11% for SZC 1.25 g, −0.16% for SZC 2.5 g, −0.21% for SZC 5 g, and –0.30% for SZC 10 g vs –0.09% for placebo (P<.001 for all except SZC 1.25 g) |
Maintenance phase: serum K+ 3.5-4.9 mEq/L at 48 h of the initial (correction) phase (n=543) | Maintenance phase: SZC dose from initial phase (administered QD) or placebo for 12 d | Maintenance phase: between-group difference in mean serum K+ during 12-d treatment period: SZC 5 g and 10 g were significantly superior to placebo in maintaining normokalemia (P=.008 and P<.001, respectively) | |
HARMONIZE: phase 3, 4-wk, randomized, double-blind, placebo-controlled
56
|
Open-label phase: serum K+ ≥5.1 mEq/L (n=258); CKD: n=169; RAASi: n=180 | Open-label phase: SZC 10 g TID for 48 h | NA |
Randomized phase: serum K+ 3.5-5 mEq/L at 48 h of the initial (open-label) phase (n=237); CKD: n=152; RAASi: n=163 | Randomized phase: SZC 5, 10, or 15 g QD or placebo for 28 d | Mean serum K+ in each dosing group vs placebo during days 8-29 of the randomized phase: 4.8 mEq/L for SZC 5 g, 4.5 mEq/L for SZC 10 g, and 4.4 mEq/L for SZC 15 g vs 5.1 mEq/L for placebo (P<.001 for all) | |
Phase 3, 12-mo, open-label, single-arm
58
|
Correction phase: serum K+ ≥5.1 mEq/L (n=751) | Correction phase: SZC 10 g TID for 24-72 h | Correction phase: proportion of patients with serum K+ 3.5-5.0 mEq/L: 78% |
Maintenance phase: serum K+ 3.5-5.0 mEq/L (n=746); CKD: n=483; RAASi: n=483 | Maintenance phase: SZC titrated to serum K+ 3.5-5.0 mEq/L (maximum 15 g QD, minimum 5 g every other day) | Maintenance phase: proportion of patients with serum K+ ≤5.1 during 3-12 mo: 88% | |
HARMONIZE-GL: phase 3, 4-wk, randomized, double-blind, placebo-controlled
80
|
Correction phase: serum K+ ≥5.1 mEq/L (n=267); CKD: n=209; RAASi: n=205 | Correction phase: SZC 10 g TID for 48 h | NA |
Maintenance phase: serum K+ 3.5-5.0 mEq/L (n=248); CKD: n=199; RAASi: n=195 | Maintenance (randomized) phase: SZC 5 or 10 g QD or placebo for 28 d | Back-transformed least squares mean serum K+ on days 8-29 of the maintenance phase: 4.81 mEq/L for SZC 5 g and 4.38 mEq/L for SZC 10 g vs 5.32 mEq/L for placebo (P<.001 for both) |
Study: design | Patient population | Study treatment | Primary efficacy end point results
c
Safety was also assessed. Patiromer may bind to magnesium ions in the colon, which can lead to hypomagnesemia. In clinical studies, 5.3% of patients treated with patiromer experienced hypomagnesemia as an adverse event. Patiromer should not be used in patients with severe constipation, bowel obstruction or impaction, including bowel motility disorders that occur postoperatively; it may be ineffective or worsen gastrointestinal conditions.37
|
---|---|---|---|
PEARL-HF: phase 2, 4-wk, double-blind, placebo-controlled, randomized
57
PEARL-HF Investigators
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
Eur Heart J. 2011; 32: 820-828
|
HF, an indication to start MRA therapy, serum K+ 4.3-5.1 mEq/L, and either (1) eGFR <60 mL/min/1.73 m2 and ≥1 HF therapy (RAASi or β-blocker) or (2) hyperkalemia resulting in RAASi or β-blocker discontinuation in the past 6 mo (n=120) | Patiromer 15 g BID or placebo (plus spironolactone 25 mg/d, titrated to 50 mg/d at week 2 if serum K+ >3.5 to ≤5.1 mEq/L) | Mean change in serum K+ from baseline to week 4: patiromer −0.22 mEq/L vs placebo +0.23 mEq/L (P<.001) |
AMETHYST-DN: phase 2, 52-wk, open-label, randomized, dose-ranging
52
|
Type 2 diabetes, eGFR 15 to <60 mL/min/1.73 m2, serum K+ >5.0 to <6.0 mEq/L, and RAASi therapy (n=306) | Patiromer 4.2, 8.4, or 12.6 g BID for serum K+ >5.0 to <6.0 mEq/L; patiromer 8.4, 12.6, or 16.8 g BID for serum K+ >5.5 to <6.0 mEq/L | Mean change in serum K+ from baseline to week 4: Mild hyperkalemia: –0.35 to –0.55 mEq/L (P<.001 vs baseline for all dose groups) Moderate hyperkalemia: –0.87 to –0.92 mEq/L (P<.001 vs baseline for all dose groups) |
OPAL-HK: phase 3, 4-wk, single-group, single-blind initial treatment phase plus an 8-wk placebo-controlled, single-blind, randomized withdrawal phase
53
|
Initial treatment phase: eGFR 15 to <60 mL/min/1.73 m2, serum K+ 5.1 to <6.5 mEq/L, and stable dose of ≥1 RAASi for ≥28 d (n=243) | Treatment phase: patiromer 4.2 g BID for serum K+ 5.1 to <5.5 mEq/L; patiromer 8.4 g BID for serum K+ 5.5 to <6.5 mEq/L | Treatment phase (mean change in serum K+ from baseline to week 4): –1.01 mEq/L (P<.001 vs baseline) |
Withdrawal phase: serum K+ ≥5.5 mEq/L at initial treatment baseline, serum K+ 3.8 to <5.1 mEq/L at end of initial treatment while receiving patiromer, and RAASi therapy (n=107) | Withdrawal phase: patiromer at previous week 4 dose or placebo | Withdrawal phase (difference for patiromer vs placebo in median change in serum K+ at week 4 or earliest visit at which serum K+ was <3.8 mEq/L or ≥5.5 mEq/L): patiromer 0 mEq/L vs placebo +0.72 mEq/L (P<.001) |
Sodium Polystyrene Sulfonate
Sodium Zirconium Cyclosilicate
- McCullough P.
- Pergola P.
- Fishbane S.
- et al.
Patiromer
- Pitt B.
- Anker S.D.
- Bushinsky D.A.
- Kitzman D.W.
- Zannad F.
- Huang I.Z.
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
- Pitt B.
- Anker S.D.
- Bushinsky D.A.
- Kitzman D.W.
- Zannad F.
- Huang I.Z.
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
- Pitt B.
- Anker S.D.
- Bushinsky D.A.
- Kitzman D.W.
- Zannad F.
- Huang I.Z.
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
- Pitt B.
- Anker S.D.
- Bushinsky D.A.
- Kitzman D.W.
- Zannad F.
- Huang I.Z.
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
- Pitt B.
- Anker S.D.
- Bushinsky D.A.
- Kitzman D.W.
- Zannad F.
- Huang I.Z.
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
- Pitt B.
- Anker S.D.
- Bushinsky D.A.
- Kitzman D.W.
- Zannad F.
- Huang I.Z.
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
Real-World Experience With K+ Binders
Conclusion
Acknowledgments
Supplemental Online Material
References
-
Global prevalence of chronic kidney disease - a systematic review and meta-analysis.PLoS One. 2016; 11e0158765
-
A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010.Kidney Int. 2015; 88: 950-957
-
Treatment of abnormalities of potassium homeostasis in CKD.Adv Chronic Kidney Dis. 2017; 24: 319-324
-
Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes.Adv Chronic Kidney Dis. 2017; 24: 315-318
-
Association between serum potassium and outcomes in patients with reduced kidney function.Clin J Am Soc Nephrol. 2016; 11: 90-100
-
Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes—a Danish population-based cohort study.Nephrol Dial Transplant. 2018; 33: 1610-1620
-
Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project [published online ahead of print August 6, 2018].(Nephrol Dial Transplant)
-
Impact of admission serum potassium on mortality in patients with chronic kidney disease and cardiovascular disease.QJM. 2017; 110: 713-719
-
Antihypertensive medications and the prevalence of hyperkalemia in a large health system.Hypertension. 2016; 67: 1181-1188
-
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.Kidney Int Suppl. 2013; 3: 1-150
-
Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials.Am J Kidney Dis. 2016; 67: 728-741
-
The public health dimension of chronic kidney disease: what we have learnt over the past decade.Nephrol Dial Transplant. 2017; 32: ii113-ii120
-
Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes.Am J Nephrol. 2017; 46: 213-221
-
The frequency of hyperkalemia and its significance in chronic kidney disease.Arch Intern Med. 2009; 169: 1156-1162
-
Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena.Kidney Int Suppl (2011). 2016; 6: 20-28
-
Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.Semin Nephrol. 2014; 34: 333-339
-
Electrolyte and acid-base disturbances in patients with diabetes mellitus.N Engl J Med. 2015; 373: 548-559
-
Physiology and pathophysiology of potassium homeostasis.Adv Physiol Educ. 2016; 40: 480-490
-
Achieving the benefits of a high-potassium, paleolithic diet, without the toxicity.Mayo Clin Proc. 2016; 91: 496-508
-
2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).JAMA. 2014; 311 ([published correction appears in JAMA. 2014;311(17):1809]): 507-520
-
2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.Circulation. 2017; 136: e137-e161
-
10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes—2019.Diabetes Care. 2019; 42: S103-S123
-
Plant-based diets in CKD.Clin J Am Soc Nephrol. 2019; 14: 141-143
-
Nutrient non-equivalence: does restricting high-potassium plant foods help to prevent hyperkalemia in hemodialysis patients.J Ren Nutr. 2016; 26 ([published correction appears in J Ren Nutr. 2016;26(6):416]?): 282-287
-
Dietary potassium intake and mortality in long-term hemodialysis patients.Am J Kidney Dis. 2010; 56: 338-347
-
Management of hyperkalaemia in chronic kidney disease.Nat Rev Nephrol. 2014; 10: 653-662
-
Adverse effects of conventional thrice-weekly hemodialysis: is it time to avoid 3-day interdialytic intervals?.Am J Nephrol. 2015; 41: 400-408
-
Serum potassium levels and mortality in hemodialysis patients: a retrospective cohort study.Am J Nephrol. 2016; 44: 179-186
-
Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).Am J Kidney Dis. 2017; 69: 266-277
-
Serum potassium, end-stage renal disease and mortality in chronic kidney disease.Am J Nephrol. 2015; 41: 456-463
-
Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review.Am J Med. 2013; 126: 264.e9-264.e24
-
Real-world treatment discontinuation of sodium polystyrene sulfonate.J Am Soc Nephrol. 2016; 27 (Abstract FR-PO786)
-
Sodium zirconium cyclosilicate: a review in hyperkalaemia.Drugs. 2018; 78 ([published correction appears in Drugs. 2019;79(5):591]): 1605-1613
-
Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer.Expert Opin Pharmacother. 2016; 17: 1435-1448
- Lokelma [prescribing information]. AstraZeneca Pharmaceuticals LP, Wilmington, DE2018
- Lokelma [summary of product characteristics]. AstraZeneca AB, Södertälje Sweden2018
- Veltassa [prescribing information]. Relypsa, Inc, Redwood City, CA2018
- Veltassa [summary of product characteristics]. Vifor Fresenius Medical Care Renal Pharma, Paris, France2018
- Kayexalate [prescribing information]. Concordia Pharmaceuticals Inc, St. Michael, Barbados2017
-
Dialysate potassium, dialysate magnesium, and hemodialysis risk.J Am Soc Nephrol. 2017; 28: 3441-3451
-
Role of dietary salt and potassium intake in cardiovascular health and disease: a review of the evidence.Mayo Clin Proc. 2013; 88: 987-995
-
Potassium Homeostasis in Health and Disease: a scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension.Am J Kidney Dis. 2017; 70: 844-858
-
Dietary approach to recurrent or chronic hyperkalaemia in patients with decreased kidney function.Nutrients. 2018; 10: 261
-
Nutritional management of chronic kidney disease.N Engl J Med. 2017; 377: 1765-1776
-
New agents in treatment of hyperkalemia: an opportunity to optimize use of RAAS inhibitors for blood pressure control and organ protection in patients with chronic kidney disease.Curr Hypertens Rep. 2016; 18: 55
-
Appendix B: Food sources of selected nutrients.in: Dietary Guidelines for Americans, 2005. 6th ed. US Government Printing Office, Washington, DC2005
-
USDA Food Composition Databases.https://ndb.nal.usda.gov/ndb/Date accessed: March 10, 2019
-
Carbohydrate quality and human health: a series of systematic reviews and meta-analyses.Lancet. 2019; 393 ([published correction appears in Lancet. 2019;393(10170):406]): 434-445
-
Cardiovascular benefits of a diet enriched in fruits and vegetables.Am J Nephrol. 2019; 49: 435-437
-
Updates in hyperkalemia: outcomes and therapeutic strategies.Rev Endocr Metab Disord. 2017; 18: 41-47
-
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: considerations for trial design and regulatory approval.Int J Cardiol. 2016; 216: 46-51
-
Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial.JAMA. 2015; 314 ([published correction appears in JAMA. 2015;314(7):731]): 151-161
-
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.N Engl J Med. 2015; 372: 211-221
-
Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia.Kidney Int. 2015; 88: 1427-1433
-
A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.Kidney Int. 2015; 88: 404-411
-
Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.JAMA. 2014; 312 ([published correction appears in JAMA. 2015;313(5):526]): 2223-2233
-
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.Eur Heart J. 2011; 32: 820-828
-
Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study.Clin J Am Soc Nephrol. 2019; 14: 798-809
-
Effects of RAAS inhibitors in patients with kidney disease.Curr Hypertens Rep. 2017; 19: 72
-
The burden of hyperkalemia in patients with cardiovascular and renal disease.Am J Manag Care. 2015; 21: s307-s315
-
Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.Am J Manag Care. 2015; 21: S212-S220
-
Effect of patiromer on hyperkalemia recurrence in older chronic kidney disease patients taking RAAS inhibitors.Am J Med. 2018; 131: 555-564.e3
-
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.ESC Heart Fail. 2018; 5: 592-602
-
An analysis of the impact of fluid overload and fluid depletion for all-cause and cardiovascular mortality [published online ahead of print January 8, 2019].(Nephrol Dial Transplant)
-
Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality.Kidney Int. 2011; 79: 250-257
-
Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients.Kidney Int. 2004; 66: 1212-1220
-
Sympathetic overactivity in chronic kidney disease: consequences and mechanisms.Int J Mol Sci. 2017; 18: 1682
-
Acid-base alterations in ESRD and effects of hemodialysis.Semin Dial. 2018; 31: 226-235
-
Current perspectives on sudden cardiac death in hemodialysis patients.Contrib Nephrol. 2018; 196: 5-12
-
Characteristics of sudden death in hemodialysis patients.Kidney Int. 2006; 69: 2268-2273
-
Serum and dialysate potassium concentrations and survival in hemodialysis patients.Clin J Am Soc Nephrol. 2007; 2: 999-1007
-
Sudden death and associated factors in a historical cohort of chronic haemodialysis patients.Nephrol Dial Transplant. 2009; 24: 2529-2536
-
Patients with complex arrhythmias during and after haemodialysis suffer from different regimens of potassium removal.Nephrol Dial Transplant. 2008; 23: 1415-1421
-
The effect of two different protocols of potassium haemodiafiltration on QT dispersion.Nephrol Dial Transplant. 2005; 20: 1148-1154
-
Predictors of 30-day hospital readmission among maintenance hemodialysis patients: a hospital's perspective.Clin J Am Soc Nephrol. 2016; 11: 1005-1014
-
Revisiting RAAS blockade in CKD with newer potassium-binding drugs.Kidney Int. 2018; 93: 325-334
-
Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review.Core Evid. 2017; 12 ([published correction appears in Core Evid. 2019;14:1]): 11-24
-
Sodium zirconium cyclosilicate in hyperkalemia.N Engl J Med. 2015; 372: 222-231
-
Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis.Am J Nephrol. 2016; 44: 404-410
Zannad F, Hsu B-G, Maeda Y, et al. Sodium zirconium cyclosilicate for hyperkalemia: results of the randomized, placebo-controlled, multi-dose HARMONIZE-GLOBAL study. Poster presented at: ASN Kidney Week; October 25, 2018; San Diego, CA. Abstract TH-PO1158.
-
Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD.Clin J Am Soc Nephrol. 2015; 10: 2136-2142
-
Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia [letter].N Engl J Med. 2015; 372: 1577-1578
-
Efficacy and safety of sodium zirconium cyclosilicate to treat hyperkalemia among patients taking renin-angiotensin-aldosterone system inhibitors in a 12-month, open-label, phase 3 study: a post hoc subgroup analysis.Circulation. 2017; 136 (Abstract 16610)
-
Safety and efficacy of sodium zirconium cyclosilicate for long-term treatment of hyperkalaemia in patients with chronic kidney disease: results from an open-label, phase 3 study.Nephrol Dial Transplant. 2018; 33 (Abstract FP071): i72
-
Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.Eur J Heart Fail. 2015; 17: 1050-1056
-
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.Eur J Heart Fail. 2015; 17: 1057-1065
-
Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.J Hypertens. 2017; 35: S57-S63
-
Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.ESC Heart Fail. 2018; 5: 257-266
-
The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.Expert Opin Drug Saf. 2018; 17 ([published correction appears in Expert Opin Drug Saf. 2018;17(5):xi]): 525-535
-
Patiromer to enable spironolactone use in the treatment of patients with resistant hypertension and chronic kidney disease: rationale and design of the AMBER study.Am J Nephrol. 2018; 48: 172-180
-
The clinical and economic burden of hyperkalemia on Medicare and commercial payers.Am Health Drug Benefits. 2017; 10: 202-210
-
Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project.J Am Heart Assoc. 2017; 6e005428
-
Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system.Int J Cardiol. 2017; 245: 277-284
-
The cost of hyperkalemia in the United States.Kidney Int Rep. 2017; 3: 385-393
-
Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.Eur J Heart Fail. 2018; 20 ([published correction appears in Eur J Heart Fail. 2019;21(4):540]): 1217-1226
-
Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes; a Danish population-based cohort study.J Am Heart Assoc. 2018; 7e008912
-
The prevalence of hyperkalemia in the United States.Curr Med Res Opin. 2018; 34: 971-978
-
DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients.Kidney Int. 2018; 94: 589-598
-
Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK Clinical Practice Research Datalink.BMC Nephrol. 2018; 19: 211
-
The relation of serum potassium concentration with cardiovascular events and mortality in community-living individuals.Clin J Am Soc Nephrol. 2017; 12: 245-252
-
Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study.Clin Nephrol. 2016; 85: 38-43
-
Single-dose sodium polystyrene sulfonate for hyperkalemia in chronic kidney disease or end-stage renal disease.Clin Kidney J. 2018; 12: 408-413
-
Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy.Clin Cardiol. 2012; 35: 32-36
-
Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease.Int Urol Nephrol. 2017; 49: 2217-2221
Chatoth DK, Spiegel DM, Weir MR, et al. Outcomes in ESRD patients on hemodialysis taking patiromer for hyperkalemia. Presented at: ASN Kidney Week; November 2, 2017; New Orleans, LA. Abstract TH-PO779.
-
Real-world evaluation of patiromer for the treatment of hyperkalemia in hemodialysis patients.Kidney Int Rep. 2018; 4: 301-309
Article info
Publication history
Footnotes
Potential Competing Interests: The author reports no conflicts of interest.
Identification
Copyright
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy